Intellia Therapeutics, Inc. (NTLA)

Intellia Therapeutics' stock price has been impacted by clinical trial developments over the past six months. In October 2025, a preplanned pause in the ATTR-CM trial for Nex-z occurred due to a serious liver toxicity event, leading to a patient death. In late January 2026, the FDA lifted the clinical hold on the MAGNITUDE-2 trial for Nex-z in hereditary ATTR amyloidosis with polyneuropathy, leading to a 6.31% stock gain. In early March 2026, the FDA also lifted the clinical hold on the MAGNITUDE Phase 3 trial for Nex-z in ATTR cardiomyopathy, resulting in a 12.05% stock increase. As of April 6, 2026, the stock price had increased by 100.60% over the last 12 months and showed a year-to-date return of 47.94%, but decreased by 1.04% in the month prior. The 52-week high for NTLA shares was $28.25, and the 52-week low was $5.90.

The demand for Intellia Therapeutics' investigational therapies is not subject to typical seasonal fluctuations. Demand is driven by clinical trial progress, regulatory approvals, and the prevalence of the specific diseases they aim to treat, rather than seasonal patterns.

Intellia Therapeutics is a clinical-stage biotechnology company focused on developing CRISPR-based gene editing therapeutics. The company's pipeline includes in vivo and ex vivo gene editing approaches. Key product candidates include Lonvo-z for Hereditary Angioedema and Nex-z for Transthyretin Amyloidosis, which is being developed in collaboration with Regeneron Pharmaceuticals, Inc. Intellia is also involved in research programs for Hemophilia B, Acute Myeloid Leukemia & B-Cell Malignancies, sickle cell disease, and immuno-oncology, collaborating with companies like Novartis, Regeneron, Avencell, SparingVision, Kyverna, and ONK Therapeutics.

Intellia Therapeutics is headquartered in Cambridge, Massachusetts, United States. Its stock is traded on NasdaqGM, Deutsche Boerse AG, and the London Stock Exchange, indicating a global reach for its financial activities, but its primary operational and research base is in the U.S.

Intellia Therapeutics' brand reputation has been influenced by scientific advancements and clinical trial challenges. The company is recognized as a leading biopharmaceutical company and a pioneer in CRISPR gene-editing technology. However, a clinical hold was placed on its ATTR-CM trial for Nex-z in October 2025 due to a patient death, raising safety concerns. The subsequent lifting of the clinical holds on both the ATTRv-PN and ATTR-CM trials for Nex-z in early 2026, with updated safety protocols, has likely helped in the recovery of its reputation.

Approximately 88.22% to 88.77% of Intellia Therapeutics' stock is held by institutional shareholders, including ARK Investment Management LLC, Vanguard Group Inc, and BlackRock, Inc. Insider ownership ranges from 1.80% to 3.10%. Caribou Therapeutics Holdco LLC is the largest individual shareholder, owning 4.74% of the company. Public companies and individual investors hold approximately 12.30% to 25.12% of the stock.